CFD 属于复杂的高风险金融工具，其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作，以及是否能够接受高额亏损的风险。
US 简体中文
國家 • United States
    實體 • The products and services listed on this website are not available in this location.
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    交易 Alnylam Pharmaceuticals, Inc. - ALNY CFD

    183.10
    1.36%
    2.41
    最低: 183.1
    最高: 187.82
    Market Trading Hours* (UTC) Opens on Thursday at 13:30

    Mon - Fri: 13:30 - 20:00

    • 概括
    • 历史数据
    • 活动
    • 收入报表
    • 资产负债表
    • 现金流
    • 所有权
    交易条件
    价差 2.41
    多头隔夜费

    Long position overnight fee

    Margin. Your investment $1,000.00
    隔夜费用 -0.025457 %
    Charges from borrowed part ($-1.02)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    前往平台
    		-0.025457%
    空头隔夜费

    Short position overnight fee

    Margin. Your investment $1,000.00
    隔夜费用 0.003235 %
    Charges from borrowed part ($0.13)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    前往平台
    		0.003235%
    隔夜费时间 21:00 (UTC)
    最小交易量 1
    货币 USD
    保证金 20%
    上市交易所 United States of America
    交易费 0%

    *Information provided by Capital.com

    Alnylam Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

    关键数据
    前收盘价* 185.62
    开仓* 186.77
    1 年变化* 46.5%
    日范围* 183.1 - 187.82
    52 周范围 120.43-242.97
    平均交易量（10 天） 588.14K
    平均交易量（3 个月) 15.80M
    市值 23.22B
    市盈率 -100.00K
    流通股 124.53M
    收入 1.14B
    EPS -8.70
    股息（收益率 %） N/A
    贝塔 0.48
    下一个财报发布日期 Jul 26, 2023

    所有数据都是由Refinitiv提供的， 除了标有星号的数据， 这是*由 Capital.com 提供的数据

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date 平仓 Change Change (%) 開倉 High Low
    May 30, 2023 185.62 0.92 0.50% 184.70 189.35 184.53
    May 26, 2023 187.24 4.01 2.19% 183.23 188.74 183.23
    May 25, 2023 185.27 2.10 1.15% 183.17 186.12 181.22
    May 24, 2023 185.44 -2.41 -1.28% 187.85 189.95 185.44
    May 23, 2023 191.21 -0.76 -0.40% 191.97 194.50 189.92
    May 22, 2023 192.02 2.96 1.57% 189.06 192.97 188.67
    May 19, 2023 190.63 0.58 0.31% 190.05 192.50 188.73
    May 18, 2023 188.86 -2.11 -1.10% 190.97 191.30 185.90
    May 17, 2023 192.53 2.41 1.27% 190.12 193.64 185.70
    May 16, 2023 190.81 -10.42 -5.18% 201.23 201.23 188.77
    May 15, 2023 205.24 0.72 0.35% 204.52 207.90 201.77
    May 12, 2023 205.24 0.53 0.26% 204.71 207.96 203.69
    May 11, 2023 205.66 -4.28 -2.04% 209.94 209.94 203.40
    May 10, 2023 210.15 2.43 1.17% 207.72 211.54 206.93
    May 9, 2023 206.89 0.70 0.34% 206.19 209.46 203.65
    May 8, 2023 209.10 1.15 0.55% 207.95 211.00 204.86
    May 5, 2023 211.26 3.05 1.46% 208.21 212.31 206.22
    May 4, 2023 204.60 3.28 1.63% 201.32 206.08 197.94
    May 3, 2023 198.68 -1.15 -0.58% 199.83 202.50 197.79
    May 2, 2023 198.71 -1.42 -0.71% 200.13 202.79 197.66

    Alnylam Pharmaceuticals, Inc. Events

    时间（协调世界时） (UTC) 国家/地区 事件
    Wednesday, July 26, 2023

    时间（协调世界时） (UTC)

    12:30

    国家/地区

    US

    事件

    Q2 2023 Alnylam Pharmaceuticals Inc Earnings Release
    Q2 2023 Alnylam Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    Wednesday, October 25, 2023

    时间（协调世界时） (UTC)

    12:30

    国家/地区

    US

    事件

    Q3 2023 Alnylam Pharmaceuticals Inc Earnings Release
    Q3 2023 Alnylam Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    查看所有活動
    • 年度
    • 每季度
    2022 2021 2020 2019 2018
    总收入 1037.42 844.287 492.853 219.75 74.908
    收入 1037.42 844.287 492.853 219.75 74.908
    总营业费用 1899.08 1552.94 1321.29 1159.18 869.017
    销售/一般/行政费用，总计 770.658 620.639 588.42 479.005 382.359
    研究与开发 883.015 792.156 654.819 655.114 505.42
    营业收入 -861.658 -708.652 -828.438 -939.431 -794.109
    利息收入（费用），非经营净值 -259.131 -124.18 -72.687 33.448 29.262
    其他，净值 -6.204 -19.312 45.525 20.73 4.173
    税前净收入 -1126.99 -852.144 -855.6 -885.253 -760.674
    税后净收入 -1131.16 -852.824 -858.281 -886.116 -762.297
    未计算非常项目前的净收益 -1131.16 -852.824 -858.281 -886.116 -762.297
    净收入 -1131.16 -852.824 -858.281 -886.116 -761.497
    普通股股东可获收益 (不含非经常性项目) -1131.16 -852.824 -858.281 -886.116 -762.297
    普通股股东可获收益 (含非經常性項目) -1131.16 -852.824 -858.281 -886.116 -761.497
    摊薄净收入 -1131.16 -852.824 -858.281 -886.116 -761.497
    摊薄后加权平均股 121.689 118.451 114.986 109.264 100.59
    扣除特别项目的每股摊薄盈利 -9.29547 -7.1998 -7.46422 -8.10986 -7.57826
    每股正常摊薄盈利 -8.88638 -7.1998 -7.46422 -8.10986 -7.71114
    非常规项目总计 0.8
    收入成本，共计 168.817 140.144 78.052 25.062 1.802
    毛利 868.601 704.143 414.801 194.688 73.106
    异常费用（收入） 76.586 0 -20.564
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    总收入 319.29 335.035 264.306 224.818 213.259
    收入 319.29 335.035 264.306 224.818 213.259
    收入成本，共计 54.869 51.266 41.116 40.808 35.627
    毛利 264.421 283.769 223.19 184.01 177.632
    总营业费用 469.097 523.649 598.932 416.504 359.991
    销售/一般/行政费用，总计 183.659 210.344 235.859 169.984 154.471
    研究与开发 230.569 262.039 245.371 205.712 169.893
    营业收入 -149.807 -188.614 -334.626 -191.686 -146.732
    利息收入（费用），非经营净值 -19.038 -32.923 -66.198 -73.717 -86.293
    其他，净值 -3.517 14.516 -5.119 -9.27 -6.331
    税前净收入 -172.362 -207.021 -405.943 -274.673 -239.356
    税后净收入 -174.101 -207.493 -405.92 -277.402 -240.341
    未计算非常项目前的净收益 -174.101 -207.493 -405.92 -277.402 -240.341
    净收入 -174.101 -207.493 -405.92 -277.402 -240.341
    普通股股东可获收益 (不含非经常性项目) -174.101 -207.493 -405.92 -277.402 -240.341
    普通股股东可获收益 (含非經常性項目) -174.101 -207.493 -405.92 -277.402 -240.341
    摊薄净收入 -174.101 -207.493 -405.92 -277.402 -240.341
    摊薄后加权平均股 124.111 123.282 122.166 120.896 120.393
    扣除特别项目的每股摊薄盈利 -1.40278 -1.68308 -3.32269 -2.29455 -1.9963
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    每股正常摊薄盈利 -1.40278 -1.68308 -2.91521 -2.29455 -1.9963
    异常费用（收入） 0 76.586
    • 年度
    • 每季度
    2022 2021 2020 2019 2018
    流动资产总额 2692.25 2808.58 2614.78 1715.86 1200.7
    现金和短期投资 2192.41 2435.56 1874.4 1536.16 1084.16
    现金等价物 866.394 819.975 496.58 547.178 420.146
    短期投资 1326.01 1615.59 1377.81 988.984 664.009
    应收账款总额，净额 237.963 198.571 602.413 43.011 18.76
    Accounts Receivable - Trade, Net 205.621 125.305 68.871 43.011 18.76
    Prepaid Expenses 132.916 88.078 62.767 80.343 73.713
    Total Assets 3546.36 3643.3 3407.06 2395.13 1574.8
    Property/Plant/Equipment, Total - Net 738.63 733.633 706.514 646.376 320.658
    Property/Plant/Equipment, Total - Gross 912.08 874.048 810.861 722.534 400.143
    Accumulated Depreciation, Total -173.45 -140.415 -104.347 -76.158 -79.485
    Long Term Investments
    Other Long Term Assets, Total 115.482 101.095 85.77 32.894 53.448
    Total Current Liabilities 767.915 695.71 585.27 352.594 179.494
    Accounts Payable 98.094 73.426 51.966 49.884 59.708
    Accrued Expenses 587.427 435.722 392.781 224.889 112.719
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 82.394 186.562 140.523 77.821 7.067
    Total Liabilities 3704.58 3055.1 2390.81 956.442 272.837
    Total Long Term Debt 1016.94 675.697 191.278 0 30
    Long Term Debt 1016.94 675.697 191.278 0 30
    Other Liabilities, Total 1919.72 1683.69 1614.27 603.848 63.343
    Total Equity -158.223 588.203 1016.25 1438.69 1301.96
    Preferred Stock - Non Redeemable, Net 0 0 0 0 0
    Common Stock 1.24 1.202 1.164 1.122 1.011
    Additional Paid-In Capital 6454.54 6058.45 5644.07 5201.18 4175.14
    Retained Earnings (Accumulated Deficit) -6569.35 -5438.19 -4585.37 -3727.09 -2840.97
    Other Equity, Total -2.392 1.163 -11.178 -3.863 -33.213
    Total Liabilities & Shareholders’ Equity 3546.36 3643.3 3407.06 2395.13 1574.8
    Total Common Shares Outstanding 123.925 120.182 116.427 112.188 101.177
    Total Inventory 128.962 86.363 75.202 56.348 24.068
    Unrealized Gain (Loss) -42.262 -34.422 -32.444 -32.655
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    流动资产总额 2541.02 2692.25 2690.85 2471.64 2589.68
    现金和短期投资 2070.68 2192.41 2265.33 2110.61 2239.56
    现金等价物 672.245 866.394 1073.23 575.558 534.081
    短期投资 1398.43 1326.01 1192.1 1535.06 1705.48
    应收账款总额，净额 219.434 237.963 184.513 142.271 156.533
    Accounts Receivable - Trade, Net 196.862 205.621 162.58 133.197 133.112
    Total Inventory 131.879 128.962 115.489 88.976 78.516
    Prepaid Expenses 119.03 132.916 125.516 129.778 115.065
    Total Assets 3391.94 3546.36 3535.25 3330.42 3433.54
    Property/Plant/Equipment, Total - Net 738.081 738.63 733.623 732.122 733.158
    Other Long Term Assets, Total 112.841 115.482 110.785 126.657 110.71
    Total Current Liabilities 673.391 767.915 772.791 657.685 605.963
    Accounts Payable 62.237 98.094 40.572 52.418 54.916
    Accrued Expenses 551.654 587.427 552.16 462.479 397.226
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 59.5 82.394 180.059 142.788 153.821
    Total Liabilities 3651.18 3704.58 3602.89 3154.38 3032.38
    Total Long Term Debt 1017.89 1016.94 1015.97 677.723 676.71
    Long Term Debt 1017.89 1016.94 1015.97 677.723 676.71
    Other Liabilities, Total 1959.9 1919.72 1814.13 1818.97 1749.71
    Total Equity -259.24 -158.223 -67.638 176.04 401.166
    Preferred Stock - Non Redeemable, Net 0 0 0
    Common Stock 1.243 1.24 1.23 1.21 1.207
    Additional Paid-In Capital 6522.09 6454.54 6336.77 6172.99 6116.56
    Retained Earnings (Accumulated Deficit) -6743.45 -6569.35 -6361.86 -5955.94 -5678.53
    Unrealized Gain (Loss) -38.137 -42.262 -45.426 -43.373 -41.639
    Other Equity, Total -0.987 -2.392 1.643 1.149 3.574
    Total Liabilities & Shareholders’ Equity 3391.94 3546.36 3535.25 3330.42 3433.54
    Total Common Shares Outstanding 124.241 123.925 122.991 120.992 120.729
    • 年度
    • 每季度
    2022 2021 2020 2019 2018
    净收入/起跑线 -1131.16 -852.824 -858.281 -886.116 -761.497
    经营活动产生的现金 -541.274 -641.693 -614.961 -278.427 -562.616
    经营活动产生的现金 44.468 47.567 34.772 17.175 6.435
    非现金物品 580.967 326.387 221.249 188.133 147.347
    Cash Taxes Paid 2.566 1.066
    已付现金利息 45.235 24.657 0.172 0.775
    营运资金的变化 -35.553 -162.823 -12.701 402.381 45.099
    投资活动产生的现金 169.354 -273.3 -435.518 -417.677 272.945
    资本支出 -72.059 -76.372 -70.361 -140.156 -126.887
    其他投资现金流量项目，总计 241.413 -196.928 -365.157 -277.521 399.832
    融资活动产生的现金 425.753 1247.12 994.979 823.184 65.47
    股票的发行（报废），净额 259.36 246.268 299.982 853.184 65.47
    债务的发行（退还），净额 135.393 500 200 -30
    现金净变化 46.403 323.107 -50.582 126.997 -224.201
    外汇效应 -7.43 -9.018 4.918 -0.083
    融资现金流项目 31 500.85 494.997
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -174.101 -1131.16 -923.663 -517.743 -240.341
    Cash From Operating Activities -166.475 -541.274 -409.296 -294.012 -171.193
    Cash From Operating Activities 14.065 44.468 30.157 19.557 9.46
    Non-Cash Items 79.698 580.967 506.088 230.706 119.651
    Changes in Working Capital -86.137 -35.553 -21.878 -26.532 -59.963
    Cash From Investing Activities -76.217 169.354 309.265 -4.626 -147.419
    Capital Expenditures -13.891 -72.059 -50.424 -33.914 -17.859
    Other Investing Cash Flow Items, Total -62.326 241.413 359.689 29.288 -129.56
    Cash From Financing Activities 46.371 425.753 362.316 65.293 34.956
    Financing Cash Flow Items 4 31 23.5 15.667 7.833
    Issuance (Retirement) of Stock, Net 42.371 259.36 202.646 49.626 27.123
    Issuance (Retirement) of Debt, Net 135.393 136.17 0
    Foreign Exchange Effects 2.176 -7.43 -9.049 -11.073 -2.238
    Net Change in Cash -194.145 46.403 253.236 -244.418 -285.894
    Cash Interest Paid 13.912 45.235 43.932 29.06
    投资者名称 投资者类型 流通股百分比 持有股份 股份变动 持有日期 换手率
    Capital World Investors Investment Advisor 13.2312 16476201 85926 2023-03-31 LOW
    Fidelity Management & Research Company LLC Investment Advisor 10.4349 12994128 -283686 2023-03-31 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 9.276 11550953 100441 2023-03-31 LOW
    Baillie Gifford & Co. Investment Advisor 6.9376 8639141 -768730 2023-03-31 LOW
    Wellington Management Company, LLP Investment Advisor/Hedge Fund 4.9418 6153777 -80309 2023-03-31 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 4.785 5958517 -112740 2023-03-31 LOW
    Dodge & Cox Investment Advisor/Hedge Fund 3.1275 3894535 -696247 2023-03-31 LOW
    T. Rowe Price Associates, Inc. Investment Advisor 3.1226 3888424 -102995 2023-03-31 LOW
    T. Rowe Price Investment Management, Inc. Investment Advisor 2.4339 3030821 -171972 2023-03-31 MED
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.2926 2854881 68339 2023-03-31 LOW
    Capital Research Global Investors Investment Advisor 1.9591 2439596 1607479 2023-03-31 LOW
    JP Morgan Asset Management Investment Advisor 1.9197 2390567 1756 2023-03-31 LOW
    Capital International Investors Investment Advisor 1.7905 2229589 223968 2023-03-31 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.3958 1738115 48186 2023-03-31 LOW
    RTW Investments L.P. Investment Advisor/Hedge Fund 1.3518 1683362 0 2023-03-31 LOW
    Avoro Capital Advisors LLC Investment Advisor/Hedge Fund 0.8874 1105000 0 2023-03-31
    Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.8134 1012846 -282241 2022-12-31 LOW
    Bellevue Asset Management AG Investment Advisor 0.7093 883250 -37963 2023-03-31 LOW
    MFS Investment Management Investment Advisor/Hedge Fund 0.6146 765352 10214 2023-03-31 LOW
    Morgan Stanley & Co. LLC Research Firm 0.6077 756685 -115421 2023-03-31 MED

    为什么选择 Capital.com？让我们的数字来说话。

    Capital.com Group

    530K+

    交易者

    87K+

    每月活跃客户

    $46M+

    每月投资额

    $31M+

    每月提取金额

    交易计算器

    如果您在特定日期（选择一个日期）开立差价合约交易并在不同日期（选择一个日期）关闭交易，计算您的假设盈亏。

    交易佣金
    0
    • 1:1
    杠杆
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    投资
    交易规模（杠杆 x 投资）：
    開倉

    平仓

    做空 做多
    過去的表現並不是未來結果的可靠指標
    盈利/盈利/亏损

    Alnylam Company profile

    关于 Alnylam Pharmaceuticals, Inc.

    Alnylam Pharmaceuticals, Inc.是一家生物制药公司。 它正在开发基于核糖核酸干扰（RNAi）的治疗方法。 它的管线包括四个产品和多个后期和早期研究RNAi疗法，集中在四个战略治疗领域（STArs）。 遗传药物；心脏-代谢疾病；肝脏传染病；以及中枢神经系统/眼部疾病。 其基于RNAi的药物包括ONPATTRO（patisiran）、GIVLAARI（givosiran）、OXUMO（lumasiran）和Leqvio（inclisiran）。 ONPATTRO是一种静脉注射的RNAi疗法，目标是转甲状腺素淀粉样变性。 GIVLAARI用于减少诱导肝脏氨基乙酰丙酸合成酶1信使RNA（mRNA），以减少与急性肝性卟啉症的发作和其他疾病表现有关的毒素。 OXLUMO是一种针对羟基酸氧化酶1的RNAi疗法，用于治疗原发性高草酸尿症1型。 Leqvio用于治疗成人高胆固醇血症。

    Industry: Biotechnology & Medical Research (NEC)

    675 W Kendall St
    CAMBRIDGE
    MASSACHUSETTS 02142-1168
    US

    收入报表

    • Annual
    • Quarterly

    人们也观看

    US100

    14,236.50 Price
    -0.950% 1D Chg, %
    多头隔夜费 -0.0255%
    空头隔夜费 0.0032%
    隔夜费时间 21:00 (UTC)
    价差 1.8

    Oil - Crude

    68.41 Price
    -1.840% 1D Chg, %
    多头隔夜费 -0.0209%
    空头隔夜费 -0.0010%
    隔夜费时间 21:00 (UTC)
    价差 0.03

    Gold

    1,965.75 Price
    +0.250% 1D Chg, %
    多头隔夜费 -0.0089%
    空头隔夜费 0.0006%
    隔夜费时间 21:00 (UTC)
    价差 0.30

    BTC/USD

    27,121.15 Price
    -2.370% 1D Chg, %
    多头隔夜费 -0.0616%
    空头隔夜费 0.0137%
    隔夜费时间 21:00 (UTC)
    价差 60.00

    还在找一位您可以信任的经纪商吗？

    加入成为全球530,000万多名交易者的一份子，选择利用Capital.com进行交易吧。

    1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易